Functionally Validated Structural Endpoints for Early AMD

Aging Clinical Trial

— ALSTAR2  

Official title:

Functionally Validated Structural Endpoints for Early AMD

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04112667
• Other study ID #: 1R01EY029595
• Status: Active, not recruiting
• Start date: October 7, 2019
• Est. completion date: August 31, 2024

Study information

• Verified date: June 2023
• Source: University of Alabama at Birmingham
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Delayed rod-mediated dark adaptation (RMDA), or delayed recovery of vision in a dark environment, is a functional biomarker (i.e., risk factor) for early age-related macular degeneration (AMD). This research plan is designed to elucidate the structural (anatomical) basis of this visual deficit using cellular- and subcellular level imaging of the retina and its supporting tissues in living people. An accurate map and timeline of structure-function relationships in persons tested for night vision will result in functionally validated structural endpoints for early AMD trials, as well as define major biologic effects for development into future treatments.

Description:

The Alabama Study on Early Age-Related Macular Degeneration 2 (ALSTAR2) is a prospective cohort study with baseline measurements that are repeated at follow-up 3 years later. The baseline and 3 year follow-up visits will each consist of 2 visits for a total of 4 visits. Study assessments are listed below. All are collected at two visits at both baseline and follow-up for 4 visits total (blood collection for DNA analysis at baseline only). For some functional tests (photopic and mesonic acuity, photopic and mesonic contrast sensitivity), each eye will be tested separately. For other functional tests (dark-adapted two-color perimetry, light-adapted cone-mediate perimetry, rod-mediated dark adaptation), only one eye will be tested, which will be designated by the study eye. Tropicamide 1% and phenylephrine hydrochloride 2.5% are used to dilate pupils (diameter of ≥ 6 mm) as needed for specific parts of the protocol. After completing the baseline visits, participants will receive an annual phone call from the study coordinator so that contact information can be updated. Participants will receive an annual newsletter containing study related information (this will be submitted to the IRB for approval). Study Assessments: 1. Rod-mediated dark adaptation (RMDA), the ability to recover light sensitivity after exposure to a bright light. 2. Dark-adapted two-color microperimetry, a measure of light sensitivity for lights of two different colors. 3. Photopic and mesopic acuity in central vision, as measured by letter charts.. 4. Photopic and mesopic contrast sensitivity in central vision, as measured by letter charts.. 5. Multimodal ocular imaging on both eyes, which consists of the following: color fundus photography, spectral domain optical coherence tomography (SDOCT), blue fundus autofluorescence (standard and quantitative), OCT-angiography (OCT-A). 6. Blood draw for the analysis of C-reactive protein, high-density lipoprotein, carotenoid level, DNA extraction, and examination of the presence of genetic risk associated with age-related macular degeneration (AMD). 7. Questionnaires: Demographics, medical co-morbidities, cognitive status screen, medication use, alcohol use, smoking, self-reported visual difficulty in the visual activities of daily living The Young normal group will only complete: 1. Rod-mediated dark adaptation (RMDA), the ability to recover light sensitivity after exposure to a bright light. 2. Dark-adapted two-color microperimetry, a measure of light sensitivity for lights of two different colors. 3. . Photopic and mesopic acuity in central vision, as measured by letter charts.. 4. Photopic and mesopic contrast sensitivity in central vision, as measured by letter charts.. 5. Multimodal ocular imaging on both eyes, which consists of the following: color fundus photography, spectral domain optical coherence tomography (SDOCT), blue fundus autofluorescence (standard and quantitative),OCT-angiography (OCT-A).d and quantitative), OCT-angiography.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 556
• Est. completion date: August 31, 2024
• Est. primary completion date: August 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

For those in Normal Macular Health or Early AMD: aged = 60 years; either have normal macular health in both eyes at baseline or have early AMD in one eye For Young Normals: aged 20-30 years old; normal macular health in both eyes. Exclusion Criteria:

Exclusion for those in normal macular health are:

• ANY EYE CONDITION OR DISEASE IN EITHER EITHER (OTHER THAN EARLY CATARACT) THAT CAN

IMPAIR VISION INCLUDING:

• diabetic retinopathy
• glaucoma
• ocular hypertension
• history of retinal diseases (e.g., retinal vein occlusion, retinal degenerations)
• optic neuritis
• corneal disease
• previous ocular trauma or surgery
• REFRACTIVE ERROR >- 6 DIOPTERS
• NEUROLOGICAL CONDITIONS THAT CAN IMPAIR VISION OR JUDGEMENT INCLUDING:
• multiple sclerosis
• Parkinson disease
• stroke
• Alzheimer disease
• seizure disorders
• brain tumor
• traumatic brain injury
• PSYCHIATRIC DISORDERS THAT COULD IMPAIR THE ABILITY:
• to follow simple directions
• answer questions about health and functioning
• or to provide informed consent
• DIABETES
• ANY MEDICAL CONDITION THAT CAUSES SIGNIFICANT FRALITY OR IS BELIEVED TO BE TERMINAL. Exclusion criteria for the early AMD group: These are identical to those described above, except that it is acceptable for participants to have early AMD (AREDS 2-4) in one eye and be AREDS grade 1 or any stage of AMD in the fellow eye.

Exclusion for Young Normals:

• ANY EYE CONDITION OR DISEASE IN EITHER EYE (OTHER THAN EARLY CATARACT) THAT CAN IMPAIR

VISION INCLUDING:

• diabetic retinopathy
• glaucoma
• ocular hypertension
• history of retinal diseases (e.g., retinal vein occlusion, retinal degenerations)
• optic neuritis, corneal disease
• previous ocular trauma or surgery
• RERACTIVE ERROR >=6 DIOPTORS
• NEUROLOGICAL CONDITIONS THAT CAN IMPAIR VISION OR JUDGEMENT INCLUDING:
• multiple sclerosis
• Parkinson disease
• stroke
• Alzheimer disease
• seizure disorders
• brain tumor
• traumatic brain injury
• PSYCHIATRIC DISORDERS THAT COULD IMPAIR THE ABILITY TO:
• follow simple directions
• answer questions about health and functioning
• or to provide informed consent
• DIABETES
• ANY MEDICAL CONDITION THAT CAUSES SIGNIFICANT FRAILTY OR IS BELIEVED TO BE TERMINAL.

Related Conditions & MeSH terms

• Age-related Macular Degeneration
• Aging
• Macular Degeneration

Intervention

Other:
• Normal Macular Health
This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
• Early Macular Degeneration
This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
• Young Normals
This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.

Locations

Country	Name	City	State
United States	University of Alabama at Birmingham	Birmingham	Alabama

Sponsors (1)

Lead Sponsor	Collaborator
Cynthia Owsley

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rod-mediated dark adaptation	Time required to recover light sensitivity after exposure to bright light	Measured at baseline enrollment
Primary	Rod-mediated dark adaptation	Time required to recover light sensitivity after exposure to bright light	Measured at 3 years after baseline enrollment
Primary	incident age-related macular degeneration (AMD) or progression of AMD using multimodal imaging	development of AMD or progression of AMD at the 3 year follow up visit	Measured at baseline enrollment
Primary	incident age-related macular degeneration (AMD) or progression of AMD using multimodal imaging	development of AMD or progression of AMD at the 3 year follow up visit	Measured at 3 years after baseline enrollment
Secondary	Light sensitivity as measured by microperimetry and perimetry	Amount of light needed to detect a small target object	Measured at baseline enrollment
Secondary	Light sensitivity as measured by microperimetry and perimetry	Amount of light needed to detect a small target object	Measured at 3 years after baseline enrollment
Secondary	Photopic and mesopic acuity	Visual acuity under day time and twilight conditions	Measured at baseline enrollment
Secondary	Photopic and mesopic acuity	Visual acuity under day time and twilight conditions	Measured at 3 years after baseline enrollment
Secondary	Photopic and mesopic contrast sensitivity	Amount of contrast needed to recognize a letter under day time and twilight conditions	Measured at baseline enrollment
Secondary	Photopic and mesopic contrast sensitivity	Amount of contrast needed to recognize a letter under day time and twilight conditions	Measured at 3 years after baseline enrollment